Related Experiment Video
Updated: Jul 30, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Ferroptosis vulnerability in FLT3-mutant leukemia
Hyemin Lee1, Li Zhuang1, Boyi Gan2
1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Resistance to FLT3 inhibition is a prevalent challenge in managing FLT3-mutant acute myeloid leukemia (AML). A recent study by Sabatier et al. discovered ferroptosis vulnerability in FLT3-mutant AML and they propose a promising therapeutic approach of combining FLT3 inhibitors with ferroptosis inducers for treating this type of cancer.
Insights
FLT3-mutant acute myeloid leukemia (AML) often resists FLT3 inhibitors. A new study reveals this cancer type is vulnerable to ferroptosis, suggesting combining FLT3 inhibitors with ferroptosis inducers as a novel treatment strategy.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- Resistance to FLT3 inhibitors presents a significant clinical hurdle in treating FLT3-mutant acute myeloid leukemia (AML).
- Identifying novel therapeutic vulnerabilities is crucial for improving outcomes in AML patients.
Purpose of the Study:
- To investigate the potential of ferroptosis as a therapeutic target in FLT3-mutant AML.
- To explore the efficacy of combining FLT3 inhibitors with ferroptosis inducers.
Main Methods:
- The study analyzed FLT3-mutant AML models to assess their susceptibility to ferroptosis.
- Experimental therapies involved the co-administration of FLT3 inhibitors and ferroptosis-inducing agents.
Main Results:
- FLT3-mutant AML cells exhibit a distinct vulnerability to ferroptosis.
- Combination therapy demonstrated enhanced anti-leukemic effects compared to single-agent treatments.
Conclusions:
- Ferroptosis induction represents a promising strategy to overcome FLT3 inhibitor resistance in AML.
- Targeting ferroptosis in combination with FLT3 inhibition offers a novel therapeutic avenue for FLT3-mutant AML.
Related Concept Videos
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...